
Search
Selected Filter
Filter Results
Displaying 1–10 of 202 diseases results
-
Jun 16, 2025
Turning RP into a Canvas of Hope
Diagnosed with retinitis pigmentosa (RP) at 12, Raquel spent years navigating vision loss without support. But everything changed when she connected with the Foundation Fighting Blindness — and found not just answers, but community. Now an artist, advocate, and leader in San Diego, Raquel uses her story and her art as the founder of Unblurred Collection to raise awareness, give back, and inspire others living with blinding diseases.
-
Jun 13, 2025
Eye on the Cure Podcast | Episode 87: Dr. Philip Beales
Dr. Philip Beales, a co-founder of Axovia Therapeutics, talks about Bardet Biedl syndrome.
-
Jun 6, 2025
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
May 30, 2025
Legacy Donor Spotlight: Dr. Debora Elliott Ward
Dr. Debora Elliott Ward, a clinical psychologist living with retinitis pigmentosa, shares her journey of resilience, professional success, and commitment to supporting the Foundation Fighting Blindness by naming it a beneficiary in her estate plans.
-
May 29, 2025
I find it difficult to explain my eyesight to people. I have retinitis pigmentosa (RP), which is a condition that progressively causes vision loss. I am legally blind, my peripheral vision is very limited, and most of what I see is blurry.
-
May 23, 2025
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Dr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
May 15, 2025
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Despite missing the primary endpoint, the treatment improved vision for some patients.
-
May 13, 2025
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
May 12, 2025
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
May 9, 2025
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.